Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1976 3
1977 1
1978 2
1979 3
1980 2
1981 3
1982 2
1983 4
1984 4
1985 3
1986 3
1987 6
1988 7
1989 7
1990 4
1991 11
1992 7
1993 4
1994 8
1995 12
1996 8
1997 20
1998 12
1999 10
2000 16
2001 16
2002 17
2003 14
2004 18
2005 13
2006 19
2007 26
2008 16
2009 28
2010 32
2011 17
2012 27
2013 37
2014 35
2015 40
2016 40
2017 44
2018 36
2019 50
2020 68
2021 65
2022 65
2023 65
2024 20

Text availability

Article attribute

Article type

Publication date

Search Results

841 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Locally Advanced Lymphoma"
Page 1
Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management.
Ansell SM. Ansell SM. Am J Hematol. 2022 Nov;97(11):1478-1488. doi: 10.1002/ajh.26717. Epub 2022 Sep 19. Am J Hematol. 2022. PMID: 36215668 Free article.
DISEASE OVERVIEW: Hodgkin lymphoma (HL) is an uncommon B-cell lymphoid malignancy affecting 8540 new patients annually and representing approximately 10% of all lymphomas in the United States. ...Patients with early-stage disease are typically treated with combined …
DISEASE OVERVIEW: Hodgkin lymphoma (HL) is an uncommon B-cell lymphoid malignancy affecting 8540 new patients annually and representi …
Primary central nervous system lymphoma.
Schaff LR, Grommes C. Schaff LR, et al. Blood. 2022 Sep 1;140(9):971-979. doi: 10.1182/blood.2020008377. Blood. 2022. PMID: 34699590 Free PMC article. Review.
Primary central nervous system lymphoma (PCNSL) is a rare extranodal lymphomatous malignancy that affects the brain, spinal cord, leptomeninges, or vitreoretinal space, without evidence of systemic involvement. ...This review provides a discussion of the clinical presentat …
Primary central nervous system lymphoma (PCNSL) is a rare extranodal lymphomatous malignancy that affects the brain, spinal cord, lep …
NK-/T-cell lymphomas.
Wang H, Fu BB, Gale RP, Liang Y. Wang H, et al. Leukemia. 2021 Sep;35(9):2460-2468. doi: 10.1038/s41375-021-01313-2. Epub 2021 Jun 11. Leukemia. 2021. PMID: 34117356 Free PMC article. Review.
Natural killer/T-cell lymphoma (NKTL) is a sub-type of Epstein-Barr virus (EBV)-related non-Hodgkin lymphomas common in Asia and Latin America but rare elsewhere. Its pathogenesis is complex and incompletely understood. Lymphoma cells are transformed from NK- …
Natural killer/T-cell lymphoma (NKTL) is a sub-type of Epstein-Barr virus (EBV)-related non-Hodgkin lymphomas common in Asia a …
Conjunctival Lymphoma.
McGrath LA, Ryan DA, Warrier SK, Coupland SE, Glasson WJ. McGrath LA, et al. Eye (Lond). 2023 Apr;37(5):837-848. doi: 10.1038/s41433-022-02176-2. Epub 2022 Jul 26. Eye (Lond). 2023. PMID: 35882984 Free PMC article. Review.
The majority of conjunctival lymphoma is extranodal marginal zone B-Cell lymphoma (EMZL), however diffuse large B-cell (DLBCL), follicular (FL), mantle cell (MCL) and T- cell subtypes are also seen. ...Although conjunctival lymphoma is generally considered an …
The majority of conjunctival lymphoma is extranodal marginal zone B-Cell lymphoma (EMZL), however diffuse large B-cell (DLBCL) …
Cutaneous T-cell lymphomas-An update 2021.
Kempf W, Mitteldorf C. Kempf W, et al. Hematol Oncol. 2021 Jun;39 Suppl 1:46-51. doi: 10.1002/hon.2850. Hematol Oncol. 2021. PMID: 34105822 Review.
Cutaneous T-cell lymphomas (CTCL) represent the majority of primary cutaneous lymphomas (CL). ...Rare, but aggressive CTCL include cutaneous primary cutaneous aggressive epidermotropic CD8-positive T-cell lymphoma and cutaneous gamma/delta T-cell lymphoma …
Cutaneous T-cell lymphomas (CTCL) represent the majority of primary cutaneous lymphomas (CL). ...Rare, but aggressive CTCL inc …
Cutaneous T-cell lymphoma: diagnosing subtypes and the challenges.
Hague C, Farquharson N, Menasce L, Parry E, Cowan R. Hague C, et al. Br J Hosp Med (Lond). 2022 Apr 2;83(4):1-7. doi: 10.12968/hmed.2021.0149. Epub 2022 Apr 14. Br J Hosp Med (Lond). 2022. PMID: 35506718 Free article. Review.
Cutaneous T-cell lymphoma is a rare type of extranodal non-Hodgkin's lymphoma that primarily affects the skin. ...Advanced stage cutaneous T-cell lymphoma has a poor prognosis with significant morbidity. ...
Cutaneous T-cell lymphoma is a rare type of extranodal non-Hodgkin's lymphoma that primarily affects the skin. ...Advanced …
Diffuse large B-cell lymphoma.
Martelli M, Ferreri AJ, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA. Martelli M, et al. Crit Rev Oncol Hematol. 2013 Aug;87(2):146-71. doi: 10.1016/j.critrevonc.2012.12.009. Epub 2013 Jan 30. Crit Rev Oncol Hematol. 2013. PMID: 23375551 Review.
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy in adults accounting for 31% of all NHL in Western Countries. ...Cure rate is particularly high in patients with limited disease with a 5-year PFS ranging from 80% to 85%; patients with advance …
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy in adults accounting for 31% of all NHL in Western Count …
Follicular lymphoma: The long and winding road leading to your cure?
Gordon MJ, Smith MR, Nastoupil LJ. Gordon MJ, et al. Blood Rev. 2023 Jan;57:100992. doi: 10.1016/j.blre.2022.100992. Epub 2022 Jul 23. Blood Rev. 2023. PMID: 35908982 Review.
Advances in biologic understanding of molecular events in lymphoma cells and the tumor microenvironment, along with novel cellular and targeted therapies, suggest this may soon change. ...We then focus on developments over the last decade in further defining follicu …
Advances in biologic understanding of molecular events in lymphoma cells and the tumor microenvironment, along with novel cell …
Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG).
Specht L, Yahalom J, Illidge T, Berthelsen AK, Constine LS, Eich HT, Girinsky T, Hoppe RT, Mauch P, Mikhaeel NG, Ng A; ILROG. Specht L, et al. Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):854-62. doi: 10.1016/j.ijrobp.2013.05.005. Epub 2013 Jun 18. Int J Radiat Oncol Biol Phys. 2014. PMID: 23790512
Radiation therapy (RT) is the most effective single modality for local control of Hodgkin lymphoma (HL) and an important component of therapy for many patients. ...Nodal and extranodal non-Hodgkin lymphomas (NHL) are covered separately by ILROG guidelines....
Radiation therapy (RT) is the most effective single modality for local control of Hodgkin lymphoma (HL) and an important compo …
CAR-T cell therapy for patients with hematological malignancies. A systematic review.
Pasqui DM, Latorraca CDOC, Pacheco RL, Riera R. Pasqui DM, et al. Eur J Haematol. 2022 Dec;109(6):601-618. doi: 10.1111/ejh.13851. Epub 2022 Sep 18. Eur J Haematol. 2022. PMID: 36018500 Review.
The available results are from studies assessing axicabtagene, lisocabtagene, and tisagenlecleucel for patients with B cell lymphoma, and the certainty of evidence ranged from very low to low for survival and progression-related outcome and for safety outcomes. Additionall …
The available results are from studies assessing axicabtagene, lisocabtagene, and tisagenlecleucel for patients with B cell lymphoma, …
841 results